The European Medicines Agency is the European Union body responsible for the scientific evaluation, supervision, and safety monitoring of medicines. Its central function is to assess applications for marketing authorisation and issue scientific opinions on which the European Commission bases legally binding authorisation decisions valid across the Union.

That division of labour is the defining feature of the European system. The agency assesses; the Commission decides. It reflects a regulatory model built as a network of national authorities rather than as a single central agency, and it explains several differences between European and American practice.

What the EMA Does

  • Evaluates marketing authorisation applications for medicines submitted through the centralised procedure.
  • Monitors safety of authorised medicines across the EU through pharmacovigilance systems and can recommend restrictions, warnings, suspension, or withdrawal.
  • Provides scientific advice to developers on trial design and evidence requirements before and during development.
  • Coordinates inspections of manufacturing sites and clinical trial conduct, carried out by national authorities.
  • Supports the clinical trials framework, including the EU portal and database through which trial authorisation and transparency operate.
  • Publishes assessment reports setting out the reasoning behind opinions, including for refused applications and withdrawals.
  • Manages orphan and paediatric frameworks, including designation and required paediatric investigation plans.

Notably, the EMA does not regulate medical devices in the way it regulates medicines. Devices are governed by the Medical Device Regulation, with conformity assessment carried out by notified bodies, though the agency has defined roles in relation to certain combination products and companion diagnostics.

How the European System Is Structured

The EMA sits at the centre of a network. Scientific assessment is carried out largely by experts nominated by national competent authorities, working through the agency's committees. Two member states are typically appointed as rapporteur and co-rapporteur for each application, leading the assessment and preparing reports that the full committee then debates.

This network model spreads expertise across the Union and builds shared capacity, at the cost of a more complex process than a single-agency model. It also means that national authorities retain substantial responsibilities, including authorisation of medicines outside the centralised procedure, inspections, national pharmacovigilance, and enforcement.

The Main Scientific Committees

  • CHMP — Committee for Medicinal Products for Human Use, responsible for opinions on human medicines.
  • PRAC — Pharmacovigilance Risk Assessment Committee, responsible for safety assessment and risk management.
  • COMP — Committee for Orphan Medicinal Products, responsible for orphan designation for rare diseases.
  • PDCO — Paediatric Committee, responsible for paediatric investigation plans.
  • CAT — Committee for Advanced Therapies, responsible for gene therapies, cell therapies, and tissue-engineered products.
  • HMPC — Committee on Herbal Medicinal Products.
  • CVMP — Committee for Medicinal Products for Veterinary Use.

Routes to Authorisation in the EU

The Centralised Procedure

A single application assessed by the EMA leading to a Commission decision valid in all member states. It is mandatory for biotechnology-derived medicines, advanced therapy medicinal products, orphan medicines, and products for defined serious conditions including cancer, HIV, diabetes, neurodegenerative disease, autoimmune conditions, and viral diseases. It is optional for other products meeting specified criteria, including significant innovation.

National and Cooperative Procedures

Products outside the mandatory scope may be authorised nationally by a member state's competent authority. The mutual recognition procedure extends an existing national authorisation to other member states; the decentralised procedure allows simultaneous application in several member states without a prior national authorisation. Disagreements between member states can be referred to the EMA for arbitration.

How an Application Is Assessed

The applicant submits a dossier covering clinical efficacy and safety, non-clinical pharmacology and toxicology, and chemistry, manufacturing, and controls, together with proposed product information. Rapporteurs lead assessment and prepare reports; the committee raises questions, and the applicant responds, typically in defined rounds that suspend the review clock.

The committee may consult scientific advisory groups or ad hoc experts, and inspections of manufacturing or trial sites may be requested. CHMP then adopts an opinion, positive or negative, by consensus or vote. A negative opinion may be re-examined at the applicant's request. Positive opinions pass to the European Commission, which adopts the binding decision.

Authorisation may carry conditions, including specific obligations to conduct post-authorisation safety or efficacy studies, risk minimisation measures, and a required risk management plan. The agency publishes a European Public Assessment Report explaining the basis of the opinion, and publishes information on refusals and withdrawn applications, which is a notable transparency feature of the system.

Special Authorisation Pathways

  • Accelerated assessment — a shortened review timetable for medicines of major public health interest or therapeutic innovation.
  • Conditional marketing authorisation — authorisation on less comprehensive data for serious conditions with unmet need, subject to binding obligations to provide further evidence, renewed annually until obligations are fulfilled.
  • Authorisation under exceptional circumstances — where comprehensive data cannot be obtained, for example in very rare conditions, with ongoing review.
  • PRIME — enhanced scientific and regulatory support for promising medicines addressing unmet need, provided early in development.
  • Compassionate use — arrangements allowing patients with serious conditions access to unauthorised medicines outside trials, implemented at national level with EMA opinions available to support consistency.

Pharmacovigilance and Post-Authorisation Safety

The EU operates one of the more structured pharmacovigilance systems internationally. Suspected adverse reactions are reported by healthcare professionals, patients, and marketing authorisation holders into EudraVigilance, the EU database, which supports signal detection. PRAC assesses signals and can recommend label changes, additional warnings, restrictions on use, or suspension.

Marketing authorisation holders must maintain a pharmacovigilance system, submit periodic safety update reports, and conduct required post-authorisation studies. Referral procedures allow formal EU-wide review of a safety or efficacy concern affecting a medicine or class, resulting in a binding Commission decision. Certain medicines are subject to additional monitoring, indicated by a black inverted triangle in product information, signalling that safety data are still accumulating.

Authorisation Versus Access

An EU marketing authorisation permits a medicine to be placed on the market across the Union. It does not determine whether any health system will pay for it. Pricing and reimbursement are national competences, decided through national health technology assessment and payer processes that assess clinical and economic value against existing options.

The result is substantial variation in real availability between member states, in both timing and scope of funded use. EU-level work on cooperation in health technology assessment aims to reduce duplication in the clinical assessment component, while leaving pricing and funding decisions national.

How the EMA Differs from the FDA

  • Decision structure. The EMA issues a scientific opinion; the European Commission takes the legal decision. The FDA both assesses and decides.
  • Assessment model. The EMA coordinates a network of national assessors; the FDA reviews primarily with in-house staff.
  • Transparency. The EMA publishes assessment reports including for refusals and withdrawals; both agencies publish substantial documentation, with differing scope and timing.
  • Scope. The EMA regulates medicines; devices are handled through notified bodies under separate legislation. The FDA regulates medicines, devices, food, and tobacco.
  • Access. An EU authorisation is Union-wide but funding is national, so approval and availability can diverge markedly between member states.

Both apply a benefit-risk standard and frequently reach similar conclusions, though differences in timing, indication wording, and population restrictions are common.

Sources

  • European Medicines Agency — centralised authorisation procedure; committee structures; conditional marketing authorisation; PRIME; pharmacovigilance and EudraVigilance
  • European Commission — marketing authorisation decisions; EU pharmaceutical legislation
  • European Union Clinical Trials Regulation and Medical Device Regulation
  • Heads of Medicines Agencies — mutual recognition and decentralised procedures
  • European Network for Health Technology Assessment cooperation frameworks